Search
Desoxyribonuclease
go.drugbank.com/drugs/DB09551ApprovedInvestigationalThe enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration [A31251]. … The mechanism of action of the enzyme involves the splitting of thymus nucleic acid into fragments approaching the size of tetranucleotides without the release of free phosphoric acid.
Alclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnIt was withdrawn from the market in the United Kingdom in 1979.
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]
Urethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Nectin-4
go.drugbank.com/bio_entities/BE0009798TargetHumansDoes not act as receptor for alpha-herpesvirus entry into cells
Synonyms: Ig superfamily receptor LNIR, Poliovirus receptor-related protein 4NKG2-A/NKG2-B type II integral membrane protein
go.drugbank.com/bio_entities/BE0010560TargetHumansImmune inhibitory receptor involved in self-nonself discrimination. … Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions (PubMed:30860984, PubMed:9430220, PubMed:9485206, PubMed:9486650).
Synonyms: NK cell receptor A, NKG2-A/B-activating NK receptorFunction: HLA-E specific inhibitory MHC class Ib receptor activityAmiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalAmiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) … This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct.
Curcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceutical_Curcuma xanthorrhiza_ oil is extracted from _Curcuma xanthorrhiza_ Roxb., a member of the ginger family (_Zingiberaceae_) that is widely distributed in the region of Southeastern Asia [A33162]. … However the principal active components of Curcuma xanthorrhiza are [DB11672] and xanthorrhizol that display a wide range of pharmacological activities and synergistic effects [F114].
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalApproval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. … Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors